目的:探讨光学相干断层扫描(OCT)和光学相干断层扫描血管造影(OCTA)在甲状腺功能异常视神经病变(DON)中的作用。
方法:关注OCT的文献研究,OCTA和DON是通过搜索PubMed,EMBASE,2023年6月20日之前的Cochrane数据库和临床试验。使用纽卡斯尔-渥太华量表评估方法学质量。使用ReviewManagerV.5.3进行定量计算。
结果:12项研究符合资格标准并被纳入。DON组整体呈现下黄斑神经节细胞复合体,与非DON组相比,上半场和下半场。此外,与非DON组相比,DON组的神经节细胞层和内丛状层较薄。DON组的视神经乳头血管密度低于非DON组。总体上看,DON组较非DON组减少了桡骨乳头周围毛细血管密度,内部光盘,乳头周围,上半球,颞叶和鼻部。此外,非DON和DON的黄斑浅表视网膜毛细血管层低于健康对照组。
结论:本研究支持OCT和OCTA指标作为DON新型生物标志物的潜在价值。眼科医生在治疗DON时应综合考虑视网膜结构和微血管。
背景:本系统综述包括来自已发表文献的数据,并免于伦理批准。结果将通过同行评审的出版物传播,并在有临床医生参与的学术会议上发表。
■CRD42023414907。
To explore the current research about the role of optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) in dysthyroid optic neuropathy (DON).
Studies in the literature that focused on OCT, OCTA and DON were retrieved by searching PubMed, EMBASE, Cochrane databases and Clinical Trial before 20 June 2023. The methodological quality was assessed using the Newcastle-Ottawa scale. The quantitative calculation was performed using Review Manager V.5.3.
Twelve studies met the eligibility criteria and were included. DON group presented lower macular ganglion cell complex in the overall, superior and inferior hemifields compared with the non-DON group. Furthermore, the ganglion cell layer and inner plexiform layer in DON group was thinner in contrast to the non-DON group. The optic nerve head vessel density was lower in the DON group than that in the non-DON group. A reduction of radial peripapillary capillary vessel density could be seen in the DON group than the non-DON group in overall, inside disc, peripapillary, superior-hemifield, temporal and nasal. Besides, the macular superficial retinal capillary layer of non-DON and DON is lower than the healthy control group.
This study supported the potential value of OCT and OCTA metrics as novel biomarkers of DON. Ophthalmologists should comprehensively consider the retinal structure and microvasculature in dealing with DON.
This systematic review included data from published literature and was exempt from ethics approval. Results would be disseminated through peer-reviewed publication and presented at academic conferences engaging clinicians.
CRD42023414907.